Failed in phase 3

Dronabinol: slow disability worsening in secondary progressive MS

secondary progressive MS · Axonal protection / ion channels / excitotoxicity

Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.

Trials
1
Running now
0
Controlled phase 2/3 trials
1
People in controlled trials
492

How the verdict was reached

Not supported in phase 3

TrialPhaseParticipantsStartedResultCounted
CUPIDPhase 34922005Missed its main goal

145 patients in the dronabinol group had EDSS score progression (0·24 first progression events per patient-year; crude rate) compared with 73 in the placebo group (0·23 first progression events per patient-year; crude rate); HR for prespecified primary analysis was 0·92 (95% CI 0·68-1·23; p=0·57).

Paper abstract		Counted

Counted: 1. Will count later: 0. Not counted: 0.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • Oct 2026Status changed from Results pending to Failed in phase 3
  • Oct 2026Status changed from Failed in phase 3 to Results pending
  • Oct 2026First listed as Failed in phase 3

Related hypotheses

Assembled by software from public sources.